421
Participants
Start Date
January 31, 2022
Primary Completion Date
March 9, 2023
Study Completion Date
March 28, 2023
EDP1815
EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Placebo
Placebo oral capsule
USA-125, Silver Spring
USA-118, Sandy Springs
USA-124, Jacksonville
USA-102, Orlando
USA-105, Miramar
USA-108, Miami
USA-115, Sweetwater
USA-120, Miami
USA-101, Fort Lauderdale
USA-126, Tampa
USA-106, Tampa
USA-131, Birmingham
USA-127, Memphis
USA-116, Louisville
USA-121, Columbus
USA-128, Concord
USA-111, Clarksville
USA-130, Ann Arbor
USA-109, Metairie
USA-119, Baton Rouge
USA-117, Frisco
USA-110, Pflugerville
USA-114, Newport Beach
USA-112, Fountain Valley
USA-123, Fremont
USA-104, Portland
USA-113, Bellevue
AUS-102, Carlton
AUS-104, Kogarah
AUS-101, Melbourne
AUS-106, Woolloongabba
BGR-105, Pleven
BGR-104, Sevlievo
BGR-101, Sofia
BGR-102, Sofia
BGR-103, Sofia
CAN-109, Barrie
CAN-108, Edmonton
CAN-105, Markham
CAN-104, Mississauga
CAN-101, Ottawa
CAN-107, Richmond Hill
CAN-103, Surrey
CAN-106, Waterloo
CAN-111, Winnipeg
DEU-105, Berlin
DEU-107, Bochum
DEU-106, Erlangen
DEU-102, Frankfurt am Main
DEU-104, Gera
DEU-101, Hamburg
DEU-103, Heidelberg
POL-104, Gdansk
POL-106, Gdynia
POL-107, Katowice
POL-105, Lodz
POL-101, Lublin
POL-102, Warsaw
POL-103, Wroclaw
Lead Sponsor
Evelo Biosciences, Inc.
INDUSTRY